Literature DB >> 30045400

Evaluation of Exponential ADC (eADC) and Computed DWI (cDWI) for the Detection of Prostate Cancer.

Alois Martin Sprinkart1, Christian Marx1, Frank Träber1, Wolfgang Block1, Daniel Thomas1, Hans Schild1, Guido Matthias Kukuk1, Petra Mürtz1.   

Abstract

PURPOSE: To directly compare different methods proposed for enhanced conspicuity and discriminability of prostate cancer on diffusion-weighted imaging (DWI) and to compare the results to original DWI images and conventional apparent diffusion coefficient (ADC) maps.
MATERIALS AND METHODS: Clinical routine prostate DWI datasets (b = 0, 50, 800 s/mm², acquired at a field strength of 3 T) of 104 consecutive patients with subsequent MR-guided prostate biopsy were included in this retrospective study. For each dataset exponential ADC maps (eADC), computed DWI images (cDWI), and additionally eADC maps for computed b-values of 2000 and 3000 s/mm² were generated (c_eADC). For each of 123 lesions, the contrast (CR) and contrast-to-noise ratio (CNR) were determined. Differences in the CR and CNR of malignant lesions (n = 83) between the different image types and group differences between benign (n = 40), low-risk (n = 53) and high-risk (n = 30) lesions were assessed by repeated measures ANOVA and one-way ANOVA with post-hoc tests. The ability to differentiate between benign and malignant and between low-risk and high-risk lesions was assessed by receiver operating characteristic (ROC) curve analyses.
RESULTS: The CR and CNR were higher for computed DWI and related c_eADC at b = 3000 s/mm² and 2000 s/mm² compared to original DWI, conventional ADC and standard eADC. For differentiation of benign and malignant lesions, conventional ADC and CR of conventional ADC were best suited. For discrimination of low-risk from high-risk lesions, the CR of c_eADC was best suited followed by the CR of cDWI.
CONCLUSION: Computed cDWI or related c_eADC maps at b-values between 2000 and 3000 s/mm2 were superior to the original DWI, conventional ADC and eADC in the detection of prostate cancer. KEY POINTS: · Prostate cancer can appear inconspicuous on original DWI800 images. · Computed DWI images at b = 2000 - 3000 s/mm² improve lesion-to-normal-tissue contrast in prostate cancer. · Contrast in computed DWI is superior to ADC and eADC at b = 800 s/mm². CITATION FORMAT: · Sprinkart AM, Marx C, Träber F et al. Evaluation of Exponential ADC (eADC) and Computed DWI (cDWI) for the Detection of Prostate Cancer. Fortschr Röntgenstr 2018; 190: 758 - 766. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 30045400     DOI: 10.1055/a-0637-9980

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  4 in total

1.  Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3.

Authors:  Yuanyuan Che; Xu Shi; Yunpeng Shi; Xiaoming Jiang; Qing Ai; Ying Shi; Fengyan Gong; Wenyan Jiang
Journal:  Mol Ther Nucleic Acids       Date:  2019-08-16       Impact factor: 8.886

2.  Improved Visualization of Prostate Cancer Using Multichannel Computed Diffusion Images: Combining ADC and DWI.

Authors:  Matthias Hammon; Marc Saake; Frederik B Laun; Rafael Heiss; Nicola Seuss; Rolf Janka; Alexander Cavallaro; Michael Uder; Hannes Seuss
Journal:  Diagnostics (Basel)       Date:  2022-06-30

3.  The presence of living endometrial cells in ovarian endometriotic cyst fluid may contribute to the recurrence of endometriosis after surgical excision of endometriomas.

Authors:  Xinxin Xu; Yichen Chen; Qin Yu; Jianzhang Wang; Ping Xu; Libo Zhu; Qiong Xu; Jing Zhang; Shuling Cui; Kewen Yu; Tiantian Li; Xinyue Guo; Xinmei Zhang
Journal:  J Ovarian Res       Date:  2022-07-30       Impact factor: 5.506

4.  Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  BMC Cancer       Date:  2020-05-27       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.